Melissa McCracken

Melissa McCracken, Ph.D., is a Principal at Nextech Invest Ltd., where she manages investments in companies pursuing emerging cancer therapies. Dr. McCracken currently serves as a board observer of IconOvir, and previously served as a board member of ImaginAb and a board observer of Silverback Therapeutics. Prior to Nextech, she was a senior associate at Third Rock Ventures. Prior to that, Dr. McCracken completed multiple internships in research and development at Amgen (NASDAQ: AMGN). She holds a B.S. in biochemistry and molecular biology from University of California, Davis, and a Ph.D. in molecular and medical pharmacology from University of California, Los Angeles, where her research focused on engineered immunity for cancer. She also completed a postdoctoral fellowship at Stanford University where her research focused on immuno-oncology.